gilenya
Novartis works in MS switch
June 11, 2013Research and Development, Sales and Marketing MS, Novartis, gilenya
Novartis’ oral MS drug Gilenya has been found to help multiple sclerosis (MS) patients who switch to it after taking …
Biogen and Elan file for Tysabri first line use in MS
January 18, 2013Sales and Marketing Biogen IDEC, EMA, Elan, FDA, MS, Tsyabri, gilenya
Biogen Idec and Elan have applied to the FDA and EMA to expand Tysabri’s use in patients with relapsing forms …
Novartis’ MS drug improves outcomes
October 15, 2012Sales and Marketing MS, Novartis, gilenya
Novartis’ multiple sclerosis (MS) drug Gilenya has demonstrated what the manufacturer calls ‘significant’ benefits for patients if used early. Results …
Genzyme MS drug approved in US
September 13, 2012Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis
US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …
Gilenya to stay on US market – but with new safety warnings
May 15, 2012Sales and Marketing EMA, FDA, Novartis, PML, gilenya
The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …
Novartis to acquire Fougera for $1.5 billion
May 3, 2012Sales and Marketing Fougera, Novartis, dermatology, generics, gilenya
Novartis will acquire the dermatology generics firm Fougera for $1.53 billion in cash. Novartis’ generic unit Sandoz is conducting the …
Novartis Q1 earnings slide down
April 26, 2012Sales and Marketing Novartis, Q1, Sandoz, generics, gilenya
Generic competition and problems at a US plant were among the reasons why Novartis’ sales and profit dipped in the …
New safety warnings recommended for Gilenya
April 20, 2012Medical Communications, Sales and Marketing EMA, Novartis, gilenya
A safety review of Novartis’ MS treatment Gilenya has concluded the drug should stay on the market, but that patients …
NICE U-turn sees Gilenya MS pill recommended
March 16, 2012Sales and Marketing MS, NICE, UK, fingolimod, gilenya
NICE has changed its mind on Novartis’ multiple sclerosis pill Gilenya, and is now recommending the drug in a subgroup …
EMA to review safety of MS drug Gilenya
January 20, 2012Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya
The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …
FDA to probe Gilenya patient death
December 21, 2011Sales and Marketing FDA, Novartis, gilenya
The FDA is investigating Novartis’s new multiple sclerosis treatment Gilenya after a patient died within hours of taking the drug. …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Discount fails to sway NICE on Gilenya
December 1, 2011Sales and Marketing NICE, Novartis, gilenya
NICE has once again rejected Novartis’ multiple sclerosis pill Gilenya despite the firm offering a patient access scheme. In its …
New MS drug shows promise for Abbott
August 10, 2011Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya
Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …
Gilenya rejected by NICE
August 5, 2011Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya
NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
